Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cord blood hope for elderly blood cancer patients

NCT ID NCT07441967

Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special chemotherapy combination followed by a single umbilical cord blood transplant in 44 patients aged 60-69 with blood cancers. The goal is to see if this approach is safe and reduces the risk of cancer returning within 180 days. Participants receive several drugs before the transplant to prepare their bodies, then are monitored for recovery and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
umbilical cord blood transplant plus chemotherapy (thiotepa, fludarabine, G-CSF, cytarabine, busulfan)
What this could lead to
If successful, this could offer a safer transplant option for elderly patients with blood cancers, potentially improving survival without relapse.
What could go wrong
This is a small, early-phase trial with only 44 participants. Risks include infection, graft-versus-host disease, and organ damage from the strong chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 69 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 60 and 69 years old (inclusive), gender not restricted. * Patients with hematological malignancies who plan to receive a single unrelated umbilical cord blood transplantation treatment * The liver and kidney functions, as well as the heart and lung functions, must meet the following requirements: 1. Serum creatinine ≤ 1.5 × ULN 2. Cardiac function: Ejection fraction \> 50% 3. Baseline oxygen saturation \> 92% 4. Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN 5. Pulmonary function: DLCO (hemoglobin-corrected) \> 65% and FEV1 \> 65% * ECOG PS≤2 * HCT-CI≤2 * Expected survival period ≥ 6 months * By signing the informed consent form, one voluntarily participates in this study and is willing and able to cooperate with the data collection in this research. Exclusion Criteria: * For those who are allergic to the drugs and their related metabolites * Any unstable systemic diseases: including but not limited to stable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 3 months before screening), myocardial infarction (within 3 months before screening), congestive heart failure (NYHA classification ≥ 3), severe arrhythmias requiring drug treatment, liver, kidney or metabolic diseases; patients with pulmonary hypertension; or diseases that, in the judgment of the investigator, pose a serious threat to the safety of the patient or affect the patient's ability to complete the study. * Active and uncontrolled infection: Hemodynamic instability related to the infection, or new symptoms or signs of infection appear, or new infection lesions are found on imaging, or persistent fever without symptoms or signs that cannot rule out the presence of an infection. * The patient is currently involved in a clinical intervention study * The patient is unable to understand the nature of the study or has not given informed consent * Other circumstances where the researcher deems the patient unsuitable for inclusion in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignancies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.